annual meeting program - American Society of Clinical Oncology

1:00 PM - 5:00 PM
GENERAL POSTER SESSION
Monday, June 7, 2010
Genitourinary Cancer
Location: S Hall A2
Tracks(s): Genitourinary Cancer
Brd. 1A The impact of neoadjuvant chemotherapy in small cell carcinoma of the
bladder: The M. D. Anderson Cancer Center experience. (Abstract #4566)
S. P. Lynch, T. T. Vu, A. M. Kamat, H. B. Grossman, R. E. Millikan, C. P. Dinney,
A. O. Siefker-Radtke
Brd. 1B Impact of dose density of adjuvant chemotherapy for locally advanced
urothelial cancer. (Abstract #4567)
T. B. Dorff, J. Cai, G. Miranda, E. C. Skinner, A. Schuckman, S. G. Groshen,
D. I. Quinn
Brd. 1C Concentration-depth profiles of mitomycin-C in the human bladder wall after
passive diffusion, thermochemotherapy, and electromotive drug
administration. (Abstract #4568)
G. Leprini, R. Massoud, S. Dolci, P. Navarra, C. Verri, F. Torelli, F. Angelini,
S. M. Di Stasi
Brd. 1D Paclitaxel-gemcitabine (P-G) for patients (pts) with advanced urothelial
cancer (UC) age > 70 years (yrs): SWOG 0028. (Abstract #4569)
D. Raghavan, C. M. Tangen, C. Moinpour, C. Gotay, K. S. Albain, S. Louie,
H. Lenz, D. I. Quinn, M. Hussain, I. Thompson, Southwest Oncology Group
Brd. 1E The impact of a bladder cancer diagnosis on smoking behavior: An
opportunity to improve care. (Abstract #4570)
J. C. Bassett, J. L. Gore, A. C. Chi, L. Kwan, K. Chamie, C. Saigal
Brd. 1F Evaluation of African American ethnicity and socioeconomic status as
prognostic factors for overall survival in bladder cancer. (Abstract #4571)
F. Jiang, A. Ziogas, J. A. Zell, S. I. Ou
Brd. 1G Gene expression profile of advanced squamous and transitional cell
carcinoma of the bladder. (Abstract #4572)
H. M. Khaled, F. Abu-Taleb, A. Zekri, R. Haggag
Brd. 1H Phase II study of gemcitabine, cisplatin, and sunitinib in patients with
advanced urothelial carcinoma (UC). (Abstract #4573)
M. D. Galsky, G. Sonpavde, B. A. Hellerstedt, S. A. McKenney, T. E. Hutson,
M. A. Rauch, Y. Wang, K. A. Boehm, L. Asmar
Brd. 2A Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma
(AUO-AB 31/05). (Abstract #4574)
S. Krege, H. Rexer, F. vom Dorp, P. Albers, P. De Geeter, T. Klotz, AUO
Brd. 2B Validation of a trimodalitiy treatment and selective organ preservation for
bladder cancer: Influence of clinical different parameters on the 15-year
long-term outcome. (Abstract #4575)
F. Krause, O. Ott, L. Haeberle, B. Wullich
Brd. 2C Correlation of disease-free survival at 2 to 3 years and 5-year overall survival
in patients with muscle-invasive bladder cancer undergoing radical
cystectomy. (Abstract #4576)
G. Sonpavde, M. M. Khan, S. P. Lerner, R. S. Svatek, E. C. Skinner,
P. I. Karakiewicz, W. Kassouf, C. P. Dinney, Y. Fradet, S. F. Shariat
Brd. 2D Comparison of HER2 amplification in primary tumors and lymph node
metastases of urinary bladder cancer. (Abstract #4577)
A. Fleischmann, R. Seiler, D. Rotzer, G. N. Thalmann
Brd. 2E Influence of age and socioeconomic status (SES) on testicular cancer (TC)
specific mortality: A population-based study of 27,948 patients.
(Abstract #4578)
S. D. Fossa, L. B. Travis, L. Chen, M. Cvancarova
359
MONDAY